PL2807165T3 - Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych - Google Patents

Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Info

Publication number
PL2807165T3
PL2807165T3 PL13740815T PL13740815T PL2807165T3 PL 2807165 T3 PL2807165 T3 PL 2807165T3 PL 13740815 T PL13740815 T PL 13740815T PL 13740815 T PL13740815 T PL 13740815T PL 2807165 T3 PL2807165 T3 PL 2807165T3
Authority
PL
Poland
Prior art keywords
expensation
pirimido
indole
derivatives
stem cells
Prior art date
Application number
PL13740815T
Other languages
English (en)
Inventor
Guy Sauvageau
Yves Gareau
Réjean RUEL
Stéphane GINGRAS
Iman FARES
Original Assignee
Université de Montréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48872865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2807165(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université de Montréal filed Critical Université de Montréal
Publication of PL2807165T3 publication Critical patent/PL2807165T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13740815T 2012-01-27 2013-01-25 Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych PL2807165T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591521P 2012-01-27 2012-01-27
PCT/CA2013/050052 WO2013110198A1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
EP13740815.9A EP2807165B1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Publications (1)

Publication Number Publication Date
PL2807165T3 true PL2807165T3 (pl) 2019-09-30

Family

ID=48872865

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13740815T PL2807165T3 (pl) 2012-01-27 2013-01-25 Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych

Country Status (27)

Country Link
US (3) US9409906B2 (pl)
EP (1) EP2807165B1 (pl)
JP (1) JP6250556B2 (pl)
KR (1) KR102098122B1 (pl)
CN (1) CN104144931B (pl)
AU (1) AU2013212457B2 (pl)
BR (1) BR112014018524B1 (pl)
CA (1) CA2862140C (pl)
CY (1) CY1121799T1 (pl)
DK (1) DK2807165T3 (pl)
ES (1) ES2733946T3 (pl)
FR (1) FR26C1003I1 (pl)
HR (1) HRP20191189T1 (pl)
HU (1) HUE044070T4 (pl)
IL (1) IL233587B (pl)
LT (2) LT2807165T (pl)
NL (1) NL301363I2 (pl)
NO (1) NO2026005I1 (pl)
NZ (1) NZ627188A (pl)
PL (1) PL2807165T3 (pl)
PT (1) PT2807165T (pl)
RS (1) RS59002B1 (pl)
SG (1) SG11201404241SA (pl)
SI (1) SI2807165T1 (pl)
SM (1) SMT201900360T1 (pl)
TR (1) TR201909582T4 (pl)
WO (1) WO2013110198A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9757378B2 (en) 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
CA2946446C (en) * 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
DK3194602T3 (da) * 2014-09-18 2020-02-17 Univ Montreal Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler
KR20230146101A (ko) * 2014-12-31 2023-10-18 안트로제네시스 코포레이션 천연 킬러 세포 및 그의 용도
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016191879A1 (en) 2015-06-05 2016-12-08 Héma-Québec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
CN105316293A (zh) * 2015-09-23 2016-02-10 广东颐养抗衰老研究院 一种体外获得造血干/祖细胞的方法
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
MX2018007987A (es) * 2015-12-28 2019-01-10 Novartis Ag Composiciones y metodos para el tratamiento de hemoglobinopatias.
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
JP2019519486A (ja) * 2016-05-07 2019-07-11 セルラリティ インコーポレイテッド ナチュラルキラー細胞を使用して急性骨髄性白血病および多発性骨髄腫を処置する方法
MY197282A (en) * 2016-08-18 2023-06-09 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
WO2018064387A1 (en) 2016-09-28 2018-04-05 Novartis Ag Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CA3077391A1 (en) 2017-09-29 2019-04-04 Intellia Therapeutics, Inc. In vitro method of mrna delivery using lipid nanoparticles
EP3700334B1 (en) 2017-10-27 2026-04-08 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
AU2018361971A1 (en) * 2017-11-03 2020-06-04 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
EP3735412B1 (en) * 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
JP7467358B2 (ja) * 2018-02-20 2024-04-15 ウニヴェルシテ・ドゥ・モントリオール 免疫応答を媒介するin vivoでのNK細胞およびDC細胞の拡大
EP4371987B9 (en) * 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
JP7853100B2 (ja) 2019-06-05 2026-04-28 オーチャード セラピューティクス(ヨーロッパ)リミテッド 真核細胞を修飾するための組成物及び方法
EP4076466B1 (en) * 2019-12-18 2026-03-11 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
JP7846007B2 (ja) 2019-12-18 2026-04-14 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
KR20220122667A (ko) 2019-12-26 2022-09-02 스미토모 파마 가부시키가이샤 조혈 줄기세포의 배양 방법
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021256977A1 (en) * 2020-06-15 2021-12-23 Subramaniam Agatheeswaran Novel methods and compounds for protein degradation
EP4711444A3 (en) * 2020-06-25 2026-04-29 Angiocrine Bioscience, Inc. Endothelial cells for mitigation of chemotherapy-induced toxicity
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
WO2022230793A1 (ja) * 2021-04-26 2022-11-03 住友ファーマ株式会社 オキセピン誘導体
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
GB202111169D0 (en) 2021-08-03 2021-09-15 Adaptimmune Ltd Methods of T cell production
CN114736862B (zh) * 2022-05-18 2024-05-28 诺航生物技术研究院徐州有限公司 一种造血干细胞培养基和造血干细胞的体外扩增方法
CN117164593A (zh) * 2023-08-31 2023-12-05 贵州省天然产物研究中心 一种嘧啶并吲哚类化合物及其制备方法和应用、抗红白血病药物
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262864A (en) * 1968-03-29 1972-02-09 Glaxo Lab Ltd Diazacarbazoles
PT633886E (pt) 1992-04-03 2001-03-30 Upjohn Co Aminas biciclicas-heterociclicas farmaceuticamente activas
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
CZ288076B6 (cs) * 1997-01-08 2001-04-11 Pharmacia & Upjohn Company Tricyklické aminy a meziprodukty pro jejich přípravu
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
JP2002543200A (ja) * 1999-04-30 2002-12-17 ニューロゲン コーポレイション 9H−ピリミド[4、5−b]インドール誘導体:CRF1特異性リガンド
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
AU771460B2 (en) 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
DE60031714T2 (de) 1999-12-06 2007-09-06 Smithkline Beecham Corp. Thrombopoietin-mimetika
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004520302A (ja) 2000-12-19 2004-07-08 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
WO2002089746A2 (en) 2001-05-09 2002-11-14 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
CA2464934A1 (en) * 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
US7414040B2 (en) 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
AU2003300522A1 (en) 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
EP1641911A2 (en) 2003-05-02 2006-04-05 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
WO2005037825A2 (en) 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
CN101189239A (zh) 2005-04-28 2008-05-28 休普基因公司 蛋白激酶抑制剂
EP1910338B1 (en) 2005-07-14 2010-08-25 Irm, Llc Heterotetracyclic compounds as tpo mimetics
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
RU2385865C2 (ru) 2005-08-15 2010-04-10 Айрм Ллк Соединения и композиции в качестве миметиков тро
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
JP2008050355A (ja) * 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および/または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
EP2155862A2 (en) * 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
PH12013501800A1 (en) 2011-03-15 2013-10-14 L Livermore Nat Security Llc Tricyclic gyrase inhibitors
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic

Also Published As

Publication number Publication date
DK2807165T3 (da) 2019-07-15
HUE044070T4 (hu) 2019-12-30
NO2026005I1 (no) 2026-01-21
CA2862140C (en) 2020-04-21
US20170334904A1 (en) 2017-11-23
EP2807165A4 (en) 2015-08-26
ES2733946T3 (es) 2019-12-03
IL233587A0 (en) 2014-08-31
SI2807165T1 (sl) 2019-08-30
BR112014018524A2 (pt) 2021-06-08
NZ627188A (en) 2015-12-24
US9409906B2 (en) 2016-08-09
IL233587B (en) 2019-11-28
HRP20191189T1 (hr) 2019-10-04
BR112014018524A8 (pt) 2017-07-11
NL301363I2 (nl) 2026-02-19
HK1203945A1 (en) 2015-11-06
JP6250556B2 (ja) 2017-12-20
US10336747B2 (en) 2019-07-02
SG11201404241SA (en) 2014-08-28
EP2807165A1 (en) 2014-12-03
LT2807165T (lt) 2019-07-25
EP2807165B1 (en) 2019-05-15
PT2807165T (pt) 2019-07-12
LTPA2026503I1 (pl) 2026-02-10
AU2013212457A1 (en) 2014-09-18
US20160222017A1 (en) 2016-08-04
RS59002B1 (sr) 2019-08-30
KR20140121454A (ko) 2014-10-15
CN104144931B (zh) 2018-04-10
CA2862140A1 (en) 2013-08-01
CN104144931A (zh) 2014-11-12
BR112014018524B1 (pt) 2023-03-28
SMT201900360T1 (it) 2019-07-11
AU2013212457B2 (en) 2017-02-16
FR26C1003I1 (fr) 2026-03-06
KR102098122B1 (ko) 2020-04-07
CY1121799T1 (el) 2020-07-31
JP2015504902A (ja) 2015-02-16
TR201909582T4 (tr) 2019-07-22
WO2013110198A1 (en) 2013-08-01
US20150011543A1 (en) 2015-01-08
HUE044070T2 (hu) 2019-09-30

Similar Documents

Publication Publication Date Title
FR26C1003I1 (fr) Dérivés de pyrimido[4,5-b]indole et leur utilisation dans l'expansion des cellules souches hématopoïétiques
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
PL2678035T3 (pl) Pochodne fenalen-1-onu, sposób ich wytwarzania i zastosowanie
DK2882850T3 (da) System for preparation of adipose-derived stem cells
HUE046216T2 (hu) 1H-pirazolo [3,4-b]piridin-származékok és terápiás alkalmazásuk
HUE053688T2 (hu) Biciklusos heterociklusos vegyületek és ezek terápiában történõ alkalmazása
IL231903A0 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
CO6801742A2 (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
HRP20181310T1 (hr) Novi heterociklički derivati i njihova uporaba
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
FR2989710B1 (fr) Protection contre le soleil
IL247798B (en) Expansion of mature stem cells in vitro
UY34018A (es) Derivados glucósidos y usos de los mismos
IL243728B (en) Indole derivatives as rorc2 inhibitors and uses thereof
IL241808B (en) History of n-(2, 3-dihydro-1h-pyrrolo [3,2-b] pyridine-5-yl)-4-quinazolinamine and n-(2, 3-dihydro-1h-indole-5-yl} – 4-quinazolinamine as perk inhibitors
PL2723743T3 (pl) Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i ich zastosowanie
EP2963013A4 (en) INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
IL230655A0 (en) N-hetero-ring-substituted amide derivatives, compositions comprising the same and uses thereof
DE112013002488T8 (de) Vesikuläre Formulierungen, Kits und Verwendungen
PL395184A1 (pl) Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu
TH1401007032A (th) การสังเคราะห์ไพร์โรโล [2,3-b] ไพริดีน
TH1401003816A (th) องค์ประกอบ, การสังเคราะห์, และ วิธีการของการใช้อนุพันธ์ฟีนิลไซโคลอัลคิลเมทธิลเอมีน